Edralbrutinib, also known as TG-1701, is a Bruton's tyrosine kinase inhibitor. Antitumor Activity of TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma. TG-1701 is as active as ibrutinib but with improved selectivity. TG-1701, in contrast to ibrutinib, does not block neither ublituximab-driven ADCC nor ADCP in vitro. In vivo xenograft studies suggested that TG-1701 synergized with ublituximab and umbralisib. Part of the mechanism is related to the pro-immune interleukin signature and infiltration of NK cells in the tumor.
MedKoo Cat#: 535191
Name: Edralbrutinib
CAS#: 1858206-58-2
Chemical Formula: C26H21F2N5O3
Exact Mass: 489.1612
Molecular Weight: 489.48
Elemental Analysis: C, 63.80; H, 4.32; F, 7.76; N, 14.31; O, 9.81
The following data is based on the product molecular weight 489.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
